콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

BM0028

Sigma-Aldrich

BMS-536924

≥98% (HPLC)

동의어(들):

4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone, BMS 536924

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C25H26ClN5O3
CAS Number:
468740-43-4
Molecular Weight:
479.96
MDL number:
MFCD20278190
UNSPSC 코드:
12352200

분석

≥98% (HPLC)

양식

powder

색상

white to beige

solubility

DMSO: 10 mg/mL, clear

저장 온도

room temp

SMILES string

CC1=CC(N2CCOCC2)=CC3=C1NC(C4=C(NC[C@@H](O)C5=CC(Cl)=CC=C5)C=CNC4=O)=N3

생화학적/생리학적 작용

BMS-536924 is a potent, orally active, ATP-competitive insulin-like growth gactor-1 receptor (IGF1R) inhibitor.
BMS-536924 is a potent, orally active, ATP-competitive insulin-like growth gactor-1 receptor (IGF1R) inhibitor that shows anticancer activities in preclinical models.

특징 및 장점

BMS-536924 is available through a partnership with Bristol-Myers Squibb (BMS). To learn more and view other BMS compounds, visit sigma.com/BMS.

법적 정보

Sold for research purposes only under agreement from BMS.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
126M4745V

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Carly Jade Dool et al.
Endocrine-related cancer, 18(6), 699-709 (2011-09-29)
Epidemiologic and experimental evidence suggest that a subset of breast cancer is insulin responsive, but it is unclear whether safe and effective therapies that target the insulin receptor (IR), which is homologous to oncogenes of the tyrosine kinase class, can
Jenny C Potratz et al.
Cancer research, 70(21), 8770-8781 (2010-10-21)
The insulin-like growth factor-1 receptor (IGF1R) is emerging as a promising therapeutic target in human cancers. In the high-risk childhood sarcomas Ewing family tumor and rhabdomyosarcoma, IGF1R-blocking antibodies show impressive antitumor activity in some but not all patients, and acquired
Beate C Litzenburger et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(1), 226-237 (2009-01-02)
This study aimed to test the ability of a new insulin-like growth factor receptor (IGF-IR) tyrosine kinase inhibitor, BMS-536924, to reverse the ability of constitutively active IGF-IR (CD8-IGF-IR) to transform MCF10A cells, and to examine the effect of the inhibitor

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.